文献速递造血干细胞移植与细胞治疗

体外光分离置换疗法在急性和慢性类固醇难治性移植物抗宿主病中的应用:不断演变的治疗格局

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape.
PubMed 文献 · Leukemia · 2022-09-24

本文综述了类固醇难治性移植物抗宿主病(GvHD)的治疗现状,指出芦可替尼在随机试验中较最佳可用疗法显示出显著更高的缓解率,但仍在缓解持久性、眼/肝/肺表现及感染并发症方面存在未满足需求。文章探讨了将芦可替尼与体外光分离置换疗法(ECP)联合以改善治疗结果的策略,并汇总了支持两者临床疗效及潜在互补作用机制的已发表证据。

要点

  • 芦可替尼在随机试验中较最佳可用疗法显示出显著更高的缓解率,对急性和慢性GvHD均有益。
  • 类固醇难治性GvHD患者预后差,亟需改善缓解持久性、眼/肝/肺表现及减少感染并发症。
  • 本文提出将芦可替尼与体外光分离置换疗法(ECP)联合的策略,并探讨其潜在互补作用机制。

核心结论

  • 本文提出将芦可替尼与体外光分离置换疗法(ECP)联合的策略,以改善类固醇难治性GvHD患者的治疗结果,并指出两者可能具有互补的作用机制。

研究设计与样本

  • 本文为综述文章,汇总了支持芦可替尼和体外光分离置换疗法(ECP)治疗GvHD临床疗效的已发表关键证据。

主要发现

  • 芦可替尼在随机试验中较最佳可用疗法显示出显著更高的缓解率,对急性和慢性GvHD均有益。
  • 类固醇难治性GvHD患者预后差,数十年来无获批药物可用。
  • 仍需改善缓解持久性、眼/肝/肺表现的缓解及减少感染并发症。

关键数值与推荐

  • 芦可替尼是一种选择性Janus激酶(JAK)1/2抑制剂。
  • 体外光分离置换疗法(ECP)是一种基于白细胞分离的免疫调节治疗,常用于包括GvHD在内的T细胞介导的免疫疾病。

临床怎么用

  • 原文提出将芦可替尼与体外光分离置换疗法(ECP)联合的策略,以改善类固醇难治性GvHD患者的治疗结果。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with steroid-refractory graft-versus-host disease (GvHD) are known to have a poor prognosis and for decades no approved drug has been available to treat this serious condition. Although ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor demonstrated significantly higher response rates in randomized trials compared to the best available therapy, and thus, is of benefit in both acute as well as chronic GvHD, there is an urgent medical need to improve results, such as durability of responses, response in eye, liver and lung manifestations and reduction of infectious complications. In this "Review" article we would like to offer strategies for improving treatment results in patients with steroid-refractory GvHD by combining ruxolitinib with extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory treatment frequently applied in T-cell mediated immune disease including GvHD. Our article explores key published evidence supporting the clinical efficacy of both ruxolitinib and ECP in the treatment of GvHD and highlights their potentially complementary mechanisms of action.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Greinix HT, Ayuk F, Zeiser R, et al. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape. Leukemia. 2022. PMID: 36153436. doi:10.1038/s41375-022-01701-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。